Clinical stage biotech company Promedior Inc. will present data from its ongoing phase 2 clinical trial of their lead investigational therapy candidate for myelofibrosis at the 20th Congress of the European Hematology Association (EHA) taking place between June 1st and 14th in Vienna, Austria. The presentation on PRM-151, which is also being studied to treat pulmonary fibrosis, will be hosted by Olga Pozdynakova of Brigham and Women’s Hospital Boston.
At the poster presentation, the physician will present additional data about the ongoing study on the company’s product candidate, including 36-week results in patients who suffer from myelofibrosis. Dr. Pozdynakova will also discuss key clinical efficacy measures associated with the disease, with a particular focus on the validation of PRM-151 and its capacity to decrease fibrosis of the bone marrow.
The presentation is entitled “Bone marrow fibrosis by WHO Grade and quantitative image analysis is reduced by PRM-151 in patients with myelofibrosis and associated with improved bone marrow morphology and increased platelet counts,” and will take place on Saturday, June 13th, between 5:15 and 6:45 pm, as announced by the company in a press release.
Promedior is studying PRM-151 in a multi-center two stage adaptive design study to evaluate both efficacy and safety of the treatment as a single agent or combined to a stable dose of ruxolitinib in patients with Primary Myelofibrosis (PMF) Post-Polycythemia Vera MF (post-PV MF) or Post-Essential Thrombocythemia MF (post-ET MF). The drug has a novel mechanism of action designed to prevent and reduce fibrosis.
According to the company, PRM-151 is recombinant human Pentraxin-2 an endogenous protein able to control monocytes and macrophages within the damaged tissue, with demonstrated anti-fibrotic proprieties, as proven in multiple preclinical models of fibrotic disease such as pulmonary fibrosis acute and chronic nephropathy liver fibrosis, as well as age-related macular degeneration.
Promedior is also studying the use of PRM-151 for the treatment of idiopathic pulmonary fibrosis (IPF) in a phase 1b study. Last year the company announced the first results of the clinical trial, showing that structural and functional imaging of IPF patients correlate with data obtained from standard pulmonary tests. The data was summarized in a poster presentation presented at the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF).
In addition, the company was granted fast track designation by the U.S. Food and Drug Administration for the PRM-151 compound, as a promising, new therapeutic for patients with myelofibrosis, as well as orphan designation in both the US and EU. The designations supports continuing evidence that PRM-151 may be a viable therapy for treating a range of diseases characterized by fibrosis.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?